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Non-steroid biologically active heterocyclic compounds (Z)-N'-(4-(2-(4-chlorophenyl)benzo[d]thiazol-3(2H)-yl) oxazol-2-
yl)-N-(4-substituted phenylimino)-3-substituted-2,3-dihydrobenzo[d]oxazole-2-carboxamidine (4a-4h) and (Z)-N'- (4-(2- 
(4-chlorophenyl)benzo[d]thiazol-3(2H)-yl)thiazol-2-yl)-N- (4-substituted phenylimino) -3-substituted-2-hydrobenzo[d] 
thiazole-2-carboxamidine (4a’-4h’) have been synthesized, tested for their antimicrobial inhibiting potential and compared 
with standard drugs Miconazole (antifungal) and Imipenem (antibacterial). Compound 4e’ is more potentially active than 
other compounds and standard drugs. The structure configuration of newly synthesized compounds has been determined by 
elemental analysis and various spectroscopic (IR, 1H and 13CNMR and GCMS) techniques. 
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Non-steroid biologically active compounds are most 
commonly used for the treatment of variety of 
disease. A variety of heterocyclic compounds and its 
derivatives have been researched in bio-organic and 
medicinal chemistry with the application of drug 
discovery. Furthermore benzothiazole and its 
derivatives constitute the active class of compounds 



















. Ultrasonication for the 
synthesis such types of compounds is of great interest in 
synthetic organic chemistry. Ultrasounds energy help 
improve the liquid–liquid interfacial area through 
emulsification, which is important for viscous films 
containing gas-filled bubbles, oscillation and cavitations 
bubbles and may activate various mechanisms 
vibrational energy is confined in small volume with 
heating, which improve liquid-liquid interfacial area to 
promote the rate of reaction
20,21
. In this article our aim is 
to produce a new series of benzothiazole derivative 
processing through thiazol and oxazol with the hope to 
get better biological action. 
 
Result and Discussion 
 
Antifungal activity 
The antifungal activity of newly synthesized 
benzothiazole derivatives exhibited a considerable 
enhancement against Aspergillus sp., Rizoctonia sp. 
and Penicillium sp. at 1, 1.5 and 2 mg/ml 
concentration. The activity is greatly enhanced at the 
higher concentration 2mg/ml. DMSO (control) has 
shown negligible activity as compare to benzothiazole 
derivatives. However, the thiazole derivatives  
(3a’-3d’ and 4a’-4h’) have shown better activity than 
the oxazole (3a-3d and 4a-4h)
22,23
. The antifungal 
experimental results of the compounds were 
compared with the standard antifungal drugs 
Miconazole. From the data (Table I) it has been also 
observed that the activity depends upon the type  
of substituent group varies in the following  
order –C2H5>–CH3>–H>–C6H5 (R) and –Cl>–OCH3 
(R’). All the compounds were highly effective  
against Aspergillus sp. at 2 mg/ml concentration. 
Compound 4e’ C32H24Cl2N6S3 {N'-(4-(2-(4-
chlorophenyl) benzo [d]thiazol-3(2H)-yl)thiazol-2-yl)- 
N-(4-chlorophenylimino)-3-ethyl-2,3-dihydrobenzo[d] 
thiazole-2-carboxamidine} is the only compound  
who show 95% activity against Aspergillus sp. at 
2mg/ml concentration. The effect is susceptible to the 
concentration of the compound used for inhibition. 
 
Minimum inhibitory concentration (MIC) 
The antibacterial screening concentrations of the 
compounds to be used were estimated from the 
minimum inhibitory concentration (MIC). Minimum 
inhibitory concentration is the lowest concentration of 
an antimicrobial agent that will inhibit the  
visible growth of microorganisms after overnight 
incubation. The MIC of the newly synthesized 




compounds was tested against bacterial strains 
through a macrodilution tube method
24
. The MIC 
values for compounds against B. subtilis, S. aureus,  
E. coli, S. typhi and P. aeruginosa were given  
in Table II. 
Antibacterial activity 
The results of the bactericidal study of the 
synthesized compounds are summarized in Table III. 
The benzothiazole derivatives, standard drug 
Imipenem (C12H17N3O4S) and DMSO solution control 
Table I — Fungicidal screening data of the newly synthesized compounds 
Compd R R’ % Inhibition of spore germination 
Aspergillus sp. (mg/ml) Penicillium sp. (mg/ml) Rizoctonia sp. (mg/ml) 
   1.0 1.5 2.0 1.0 1.5 2.0 1.0 1.5 2.0 
3c -C2H5  28 26 35 09 16 19 25 27 30 
3c’ -C2H5  31 28 38 14 21 25 29 31 33 
4a -H -Cl 60 65 74 55 58 70 50 52 59 
4b -H -OCH3 54 61 69 47 49 59 39 41 52 
4c -CH3 -Cl 73 78 81 57 59 71 50 55 67 
4d -CH3 -OCH3 68 70 74 51 56 69 47 51 60 
4e -C2H5 -Cl 77 79 86 66 69 78 59 67 70 
4f -C2H5 -OCH3 70 73 79 60 62 71 52 56 65 
4g -C6H5 -Cl 56 60 72 47 54 67 45 48 55 
4h -C6H5 -OCH3 48 55 67 45 47 58 37 40 51 
4a’ -H -Cl 65 72 81 59 63 75 55 57 65 
4b’ -H -OCH3 59 66 75 53 57 70 48 49 61 
4c’ -CH3 -Cl 80 85 89 66 69 79 59 62 75 
4d’ -CH3 -OCH3 76 79 82 58 61 75 53 58 69 
4e’ -C2H5 -Cl 82 86 95 72 77 86 68 72 79 
4f’ -C2H5 -OCH3 77 81 89 67 70 79 60 64 73 
4g’ -C6H5 -Cl 63 69 80 56 61 73 52 55 62 
4h’ -C6H5 -OCH3 55 61 73 51 55 66 45 48 58 
Miconazole (standard)  57 69 100 65 78 83 76 82 94 
 
Table II — Minimum Inhibition Concentration (MIC) values μg/ml for newly synthesized compounds and standard drug 




Bacillus subtilis Escherichia coli Salmonella typhi Pseudomonas 
aeruginosa 
3c -C2H5  63 75 105 110 110 
3c’ -C2H5  60 55 75 115 115 
4a -H -Cl 50 50 75 105 105 
4b -H -OCH3 55 65 80 100 100 
4c -CH3 -Cl 40 45 70 80 75 
4d -CH3 -OCH3 50 50 60 100 105 
4e -C2H5 -Cl 30 30 60 60 75 
4f -C2H5 -OCH3 30 40 75 60 70 
4g -C6H5 -Cl 55 55 80 100 105 
4h -C6H5 -OCH3 55 70 100 105 105 
4a’ -H -Cl 55 50 50 60 60 
4b’ -H -OCH3 40 30 40 50 90 
4c’ -CH3 -Cl 25 20 50 50 50 
4d’ -CH3 -OCH3 20 25 40 50 70 
4e’ -C2H5 -Cl 10 10 30 50 60 
4f’ -C2H5 -OCH3 15 15 35 50 50 
4g’ -C6H5 -Cl 30 30 66 75 80 
4h’ -C6H5 -OCH3 25 30 80 80 90 
Imipenem  8 8 6 6 6 
 




were screened for their antibacterial activity against 
the bacteria Staphylococcus aureus and Bacillus 
subtilis (as gram positive bacteria) and Pseudomonas 
aeruginosa, Escherichia coli and Salmonella typhi (as 
gram negative bacteria). From the bactericidal 
activity, it is  apparent   that   the   newly   synthesized 
compounds were more toxic towards gram positive 
strains than gram negative strains. The reason is the 
difference in the structure of the cell walls. The walls 
of gram negative cells are more complex than those of 
gram positive cells. Further to it, the compounds  
(3a’-3d’ & 4a’-4h’) are moderate to highly activities 
as compare to the (3a-3d & 4a-4h) towards the  
all organism and compound 4e’ C32H24Cl2N6S3  
{N'-(4-(2-(4-chlorophenyl)benzo[d]thiazol-3(2H)-yl) 
thiazol-2-yl)-N-(4-chlorophenylimino)-3-ethyl-2,3-
dihydrobenzo[d]thiazole-2-carboxamidine} was more 
effective than standard drug. The variation in the 
antimicrobial activity of different compounds against 
different microorganisms depends on their 
impermeability of the cell or the differences in 
ribosomes in microbial cell
25
. The lipid membrane 
surrounding the cell favors the passage of any lipid 
soluble materials and it is known that liposolubility is an 
important factor controlling antimicrobial activity
26
. 
In the present study low activity of the compounds 
is may be due to their low lipophilicity, because of 
which penetration of the compounds through the lipid 
membrane was decreased and hence, they could 
neither block nor inhibit the growth of the 
microorganism. HPLC was used to analyze the 
lipophilicity of the compounds (linear regression 
analysis)
26
. RP-HPLC method flow rate of 1 mL/min, 
an injection volume of 5 µL, a column temperature of 
25°C, the UV detection at 254 nm and a 25 min 
isocratic mobile phase methanol, 25 mmol KH2PO4, 






The entire chemicals used were of the analytical 
reagent grade, 2-(4-chlorophenyl)-2,3-dihydrabenzo 
[d]thiazol, 2-chloroacetyl chloride, thiourea, urea and 
substituted aniline procured from s.d.-fine. Glacial 
acetic acid, HCl, ethanol, methanol and calcium 
chloride purchased from Merck. 
 
Synthesis 
Starting compound (1) 2-chloro-1-(2-(4-
chlorophenyl)benzo[d]thiazol-3(2H)-yl) ethanone was 
Table III — Bactericidal screening data of the newly synthesized compounds (inhibition zone in mm) 




Bacillus subtilis Escherichia coli Salmonella typhi Pseudomonas 
aeruginosa 
3c -C2H5  47 39 22 20 15 
3c’ -C2H5  51 55 25 18 12 
4a -H -Cl 60 59 40 33 29 
4b -H -OCH3 57 54 37 29 25 
4c -CH3 -Cl 64 60 40 36 34 
4d -CH3 -OCH3 59 58 36 30 27 
4e -C2H5 -Cl 70 68 51 48 40 
4f -C2H5 -OCH3 68 65 47 44 39 
4g -C6H5 -Cl 56 55 35 33 26 
4h -C6H5 -OCH3 52 47 32 23 22 
4a’ -H -Cl 69 67 47 41 38 
4b’ -H -OCH3 65 63 45 37 33 
4c’ -CH3 -Cl 72 70 49 44 41 
4d’ -CH3 -OCH3 68 66 44 39 35 
4e’ -C2H5 -Cl 81 79 59 54 51 
4f’ -C2H5 -OCH3 77 73 55 51 47 
4g’ -C6H5 -Cl 65 64 44 37 34 
4h’ -C6H5 -OCH3 61 58 39 32 31 
Imipenem  100 100 100 100 100 
aExcellent activity (90-100% inhibition), Good activity (60-70% inhibition), Significant activity (30-50% inhibition), negligible activity 
(08-20% inhibition), 
 bImipenem = Standard drug 
 
 




synthesized by reaction between 2-(4-chlorophenyl)-
2,3-dihydrobenzo[d]thiazole and 2-chloroacetyl 
chloride. Resulting compound on reaction with  
urea/ thiourea produced 4-(2-(4-chlorophenyl)benzo 
[d]thiazol-3(2H)-yl)oxazol-2-amine (2) and 4-(2- 
(4-chlorophenyl)benzo[d]thiazol-3(2H)-yl)thiazol-2-
amine (2’), respectively. Synthesized compounds 2 
and 2’ on reaction with 3-substituted-2-hydrobenzo 
[d]thiazole-2-carbaldehyde in the presence  of  glacial 
acetic acid produced 4-(2-(4-chlorophenyl) 
benzo[d]thiazol-3(2H)-yl)-N-((3-substituted-2, 
3-dihydrobenzo[d]thiazol-2-yl)methylene)oxazol- 
2-amine (3a-3d) and 4-(2-(4-chlorophenyl) benzo 
[d]thiazol-3(2H)-yl)-N-((3-substituted-2,3-
dihydrobenzo[d]thiazol-2-yl)methylene)thiazol-2-
amine (3a’-3d’) which on further reaction with 
substituted aniline (diazonium salt) synthesized  
the next product (Z)-N'-(4-(2-(4-chlorophenyl) 
benzo[d]thiazol-3(2H)-yl)oxazol-2-yl)-N-(4-substituted 
phenylimino)-3-substituted-2,3-dihydrobenzo[d] 




carboxamidine (4a’-4h’). A S7 type sonotrode was 
submerged up to 25 mm into the reactant. The ultrasonic 
wave cycle, its amplitude as well as the time of the 
reaction was adjusted by the controller. Under these 
parameters reactions were carried out for 5 to 12 
minutes. After completion of the reaction, the unreacted 
solvent was recovered in a rotarvapour flask under 
reduce pressure. The precipitate was separated washed 
with ethanol and recryltalized by suitable solvent. 




Scheme I — Synthesis of oxazol/ thiaxol substituted benzothiazole derivative 




Synthesis of 2-chloro-1-(2-(4-chlorophenyl)benzo[d] 
thiazol-3(2H)-yl) ethanone ( 1) 
Synthesis of compound (1): A solution of 2- 
(4-chlorophenyl)-2,3-dihydrobenzo[d]thiazole (0.01 
mol) in dioxane (15 mL) was added dropwise to a hot 
solution (40
o
C) of 2-chloroacetyl chloride (0.01 mol) 
in dioxane (20 mL). The reaction mixture was taken 
in an Erlenmeyer type flask and assisted by ultrasonic 
irradiation for 08 min. the progress of the reaction 
was monitored by TLC. After complete the reaction 
product was cooled and poured into ice cold water a 
precipitate was appeared. The resulting precipitate 
was filtered off, washed and recrystallised by ethanol. 
Analytical data for C15H11Cl2NOS (324.22) Calcd C, 
55.57; H, 3.42; N, 4.32; Found: C, 55.55; H, 3.50; N, 
4.36, M.p. 253
o







 (C―C), 1245 cm
–1
 (C―N), 1540 
cm
–1





 (C―S), 3040 cm
–1
 (C―H for 
aromatic compound), 
1
H NMR (DMSO-d6) δ in ppm 
3.40 (s, 2H, ―CH2Cl), 7.65-6.85 (m, 8H, Ar―H), 
4.95 (s, IH, CH of benzothiazole), 
13
C-NMR (75 
MHz, CDCl3) δ 165.8, 140.0, 134.1, 132.7, 129.2, 
128.9, 127.0, 125.4, 124.6, 121.8, 57.5, 40.2, FAB 
mass peaks [M
+
] m/e 323.22, 288.03, 276.76, 246.74, 




Synthesis of compound (2): The solution of 2-
chloro-1-(2-(4-chlorophenyl) benzo[d]thiazol-3(2H)-
yl)ethanone (compound 1) (0.01 mol) in ethanol  
(25 mL) was added to urea (0.01 mol). The reaction 
mixture was taken in an Erlenmeyer type flask and 
assisted by ultrasonic irradiation for 06 min. the 
progress of the reaction was monitored by TLC. After 
completion of the reaction product was cooled and 
poured into ice cold water. The resulting precipitate 
was filtered off, washed with ethanol and 
recrystallised by ethanol/water. The elemental 
analysis (CHN) and physical characterization data of 





 (C―Cl), 762 cm
–1





 (C=C for aromatic compound), 
1075 cm
–1
 (C―O―C), 3040 cm
–1
 (C―H for 
aromatic compound), 1579 cm
–1





H NMR (DMSO-d6) δ in ppm 4.94 (s, IH, 
CH of benzothiazole), 6.12 (s, 2H, ―NH2), 7.65-6.85 
(m, 8H, Ar―H), 7.74 (s, H, ―CH of oxazole). 
13
C-
NMR (75 MHz, CDCl3) δ 162.3, 141.6, 140.0, 138.1, 
132.7, 129.2, 128.9, 127.6, 126.0,125.4, 117.4, 113.7, 
65.5, 40.0, FAB mass peaks [M
+
] m/e 328.80, 313.78, 
294.35, 279.32, 246.01, 203.23, 136.20, 111.55, 




Synthesis of compound (3a-3d): A solution of 4-(2-
(4-chlorophenyl)benzo[d] thiazol-3(2H)-yl) oxazol-2-
amine (compound 2) (0.01 mol) in ethanol (75 mL) 
was added to 3-substituted-2-hydrobenzo[d]thiazole-
2-carbaldehyde (0.01 mol) in the presence of 2-3 drop 
of glacial acetic acid. The reaction mixture was taken 
in an Erlenmeyer type flask and assisted by ultrasonic 
irradiation for 10 min. The progress of the reaction 
was monitored by TLC. The solvents were recovered 
under reduce pressure, then the product was cooled 
and poured in to ice cold water, The resulting 
precipitate was filtered off, washed with ethanol and 
recrystallised by ethanol/water. The CHN and 
physical characterization data of the compounds is 














 (C―N), 1545 cm
–1
 (C=C  
for aromatic compound), 1052 cm
–1
 (C―O―C),  
3040 cm
–1
 (C―H for aromatic compound), 1577 cm
–1
 
Table IV — Physical characterization and elemental analysis of 4-(2-(4-chlorophenyl)benzo[d]thiazol-3(2H)-yl)-N-((3-substituted-2,3-
dihydrobenzo[d]thiazol-2-yl)methylene)oxazol-2-amine (3a-3d) 
Compd R Mol. formula Mol. Wt. m.p. (°C) Recrystallising 
solvent  
Yield % Elemental analysis 
C% H% N% 
Calcd Found Calcd Found Calcd Found 
2  C16H12ClN3OS 329.80 152 Ethanol/water 60 58.27 58.23 3.67 3.66 12.74 12.77 
3a -H C24H17ClN4OS2 477.00 160 Ethanol 62 60.43 60.44 3.59 3.56 11.75 11.77 
3b -CH3 C25H19ClN4OS2 491.02 166 Ethanol/water 61 61.15 61.16 3.90 3.93 11.41 11.45 
3c -C2H5 C26H21ClN4OS2 505.05 170 Methanol 55 61.83 61.88 4.19 4.18 11.09 11.12 
3d -C6H5 C30H21ClN4OS2 553.09 178 Ethanol/water 59 65.15 65.16 3.83 3.86 10.13 10.17 
 








H NMR (DMSO-d6) δ 
4.90 (s, 2H, ―CH of benzothiazole), 7.71 (s, H, 
―CH of oxazole), 7.65-6.85 (m, 12H, Ar―H), 8.12 
(N=CH―Ar), 9.30 (s, 1H, ―NH of benzothiazole 
exchangeable with D2O). 
13
C-NMR (75 MHz, CDCl3) 
δ 171.1, 163.7, 150.6, 146.6, 141.6, 140.0, 138.1, 
132.7, 129.2, 128.9, 127.6, 126.0, 125.4, 124.3, 117.4, 
113.7, 66.5, 57.5. FAB mass peaks [M
+
] m/e 476.00, 
427.52, 313.02, 279.32, 246.74, 230.26, 203.23, 









 (C―Cl), 760 cm
–1
 
(C―C), 1240 cm 
–1
 (C―N), 1540 cm
–1
 (C=C for 
aromatic compound), 1060 cm
–1
 (C―O―C), 3040 cm
–1
 





NMR (DMSO-d6) δ 2.34 (s, 3H, CH3), 4.90 (s, 2H, CH 
of benzothiazole), 7.69 (s, H, ―CH of oxazole), 7.71-
6.85 (m, 12H, Ar―H), 8.13 (N=CH―Ar). 
13
C-NMR 
(75 MHz, CDCl3) δ 171.1, 163.7, 146.6, 141.6, 140.0, 
138.1, 132.7, 129.2, 128.9, 127.6, 126.1, 125.4, 125.1, 
124.3, 118.5, 114.5, 66.5, 61.9, 40.0, 34.3. FAB mass 
peaks [M
+
] m/e 490.06, 455.10, 428.52, 313.78, 279.32, 
246.74, 203.02, 177.25, 150.22, 136.20, 111.55, 95.07, 













 (C―N), 1545 cm
–1
 (C=C for 
aromatic compound), 1080 cm
–1
 (C―O―C), 3044 
cm
–1





H NMR (DMSO-d6) δ 2.35 (t, 3H, CH3), 4.22 
(q, 2H, CH2), 4.90 (s, 2H, CH of benzothiazole), 7.68 
(s, H, ―CH of oxazole), 7.75-6.75 (m, 12H, Ar―H), 
8.11 (N=CH―Ar). 
13
C-NMR (75 MHz, CDCl3) δ 
171.1, 163.7, 146.6, 142.6, 141.6, 140.0, 138.1, 132.7, 
129.2, 128.9, 127.6, 126.1, 125.4, 125.1, 124.3, 118.5, 
114.5, 66.5, 59.4, 41.2, 12.3. FAB mass peaks [M
+
] 
m/e 504.05, 490.01, 475.99, 469.60, 313.78, 279.02, 
258.31, 246.74, 203.02, 191.28, 177.23, 136.20, 




methylene) oxazol-2-amine (3d) 









 (C―N), 1545 cm
–1
 (C=C for 
aromatic compound), 1070 cm
–1
 (C―O―C), 3044 
cm
–1





H NMR (DMSO-d6) δ 4.90 (s, 2H, CH of 
benzothiazole), 7.67 (s, H, ―CH of oxazole), 7.85-
6.85 (m, 17H, Ar―H), 8.11 (N=CH―Ar). 
13
C-NMR 
(75 MHz, CDCl3) δ 171.1, 163.7, 149.1, 141.3, 140.0, 
138.1, 125.4, 132.7, 129.9, 129.7, 129.2, 128.9, 127.7, 
126.1, 125.4, 124.3, 118.3, 117.4, 113.7, 66.5, 61.8. 
FAB mass peaks [M
+
] m/e 552.09, 517.74, 475.99, 
441.54, 313.78, 306.07, 246.74, 239.32, 212.29, 
203.23, 136.20, 111.55, 95.07, 77.10, 68.04, 28.05. 
 




Synthesis of compound (4a-4h): A solution of the 
compound 3a-3d (0.1 mol) in ethanol was added to a 
solution of diazonium salt {(prepared by chloro/ 
methoxy substituted aniline (0.1 mol) in glacial acetic 
(4mL) was added to conc. HCl (2mL) at 0-4
o
C and 
20% sodium nitrite solution (2mL)} with constant 
stirring in pyridine (20 mL) below 0
o
C. The reaction 
mixture was taken in an Erlenmeyer type flask and 
assisted by ultrasonic irradiation for 05 min. in ice 
bath. The progress of the reaction was monitored by 
TLC. The resulting solids were washed with water, 
recrystallised from ethanol and dried under vacuum 
over anhydrous CaCl2. Their CHN and physical 

























 (C―H for aromatic 
compound), 1577 cm
–1





NMR (DMSO-d6) δ 4.90 (s, 2H, ―CH of 
benzothiazole), 7.65-6.75 (m, 16H, Ar―H), 7.72 (s, 
H, ―CH of oxazole), 8.14 (N=CH―Ar), 9.30 (s, 1H, 
―NH of benzothiazole exchangeable with D2O). 
13
C-
NMR (75 MHz, CDCl3) δ 150.6, 146.6, 141.6, 140.0, 
138.1, 134.3, 132.7, 130.2, 129.2, 128.9, 127.6, 126.8, 
126.0, 125.4, 124.3, 117.4, 113.7, 66.5, 58.0. FAB 
mass peaks [M
+
] m/e 614.55, 567.08, 445.64, 368.03, 
313.78, 301.77, 246.01, 230.24, 233.62, 203.02, 
191.25, 163.21, 158.27, 136.18, 123.07, 111.54, 
77.09, 68.04, 56.03. 


























 (C―H for aromatic 
compound), 1561 cm
–1





NMR (DMSO-d6) δ 3.39 (s, 3H, ―OCH3), 4.90 (s, 
2H, ―CH of benzothiazole), 7.65-6.75 (m, 16H, 
Ar―H), 7.71 (s, H, ―CH of oxazole), 8.17 
(N=CH―Ar), 9.30 (s, 1H, ―NH of benzothiazole 
exchangeable with D2O). 
13
C-NMR (75 MHz, CDCl3) 
δ 150.6, 146.6, 142.6, 141.6, 140.0, 138.1, 134.3, 
132.7, 130.2, 129.2, 128.9, 127.6, 126.8, 126.0, 125.4, 
124.3, 117.4, 113.7, 66.5, 57.4, 34.3. FAB mass peaks 
[M
+
] m/e 610.13, 580.10, 575.68, 475.99, 393.45, 
364.40, 313.78, 297.35, 246.01, 230.24, 203.02, 






























H NMR (DMSO-d6) δ 
2.35 (s, 3H, ―CH3), 4.90 (s, 2H, ―CH of 
benzothiazole), 7.65-6.75 (m, 16H, Ar―H), 7.69 (s, 
H, ―CH of oxazole), 8.12 (N=CH―Ar). 
13
C-NMR 
(75 MHz, CDCl3) δ 150.8, 142.6, 141.6, 140.0. 138.1, 
134.3, 132.7, 130.2, 129.2, 128.9, 127.6, 126.8, 
126.1,126.0, 125.4, 125.1, 18.5, 117.4, 114.5, 
113.7,66.5, 54.9, 41.2, 12.3. FAB mass peaks [M
+
] 
m/e 628.58, 594.12, 518.03, 463.98, 382.05, 313.78, 
272.12, 246.01, 244.28, 230.24, 203.02, 177.23, 































H NMR (DMSO-d6) δ 
2.39 (s, 3H, ―CH3), 3.41 (s, 3H, ―OCH3), 4.91 (s, 
2H, ―CH of benzothiazole), 7.69 (s, H, ―CH of 
oxazole), 7.75-6.75 (m, 16H, Ar―H), 8.11 
(N=CH―Ar). 
13
C-NMR (75 MHz, CDCl3) δ 150.6, 
149.1, 141.6, 140.0. 138.1, 134.3, 132.7, 130.2, 129.7, 
129.2, 128.9, 127.7, 126.8, 126.1, 126.0, 125.4, 125.1, 
119.3, 118.5, 118.3, 117.4, 114.6, 113.7, 66.5, 57.3. 
FAB mass peaks [M
+
] m/e 624.16, 594.12, 589.70, 
513.61, 378.42, 313.78, 311.38, 246.01, 244.28, 
230.24, 203.02, 177.23, 162.16, 150.22, 136.18, 





























H NMR (DMSO-d6) δ 
2.35 (s, 3H, ―CH3), 4.24 (q, 2H, ―CH2), 4.91 (s, 2H, 
―CH of benzothiazole), 7.67 (s, H, ―CH of 
oxazole), 7.75-6.75 (m, 16H, Ar―H), 8.13 
(N=CH―Ar). 
13
C-NMR (75 MHz, CDCl3) δ 160.7, 
150.7, 146.6, 141.6, 140.0, 138.1, 129.8, 129.2, 128.9, 
127.6, 126.0, 125.4, 124.3, 117.4, 114.3, 113.7, 66.5, 
Table V — Physical characterization and elemental analysis of (Z)-N'-(4-(2-(4-chlorophenyl)benzo[d]thiazol-3(2H)-yl)oxazol-2-yl)-N- 
(4-substituted phenylimino)-3-substituted-2,3-dihydrobenzo[d]thiazole-2-carboxamidine (4a-4h) 











C% H% N% 
Calcd Found Calcd Found Calcd Found 
4a -H -Cl C30H20Cl2N6OS2 615.55 242 Ethanol 56 58.54 55.55 3.27 3.29 13.65 13.67 
4b -H -OCH3 C31H23ClN6O2S2 611.13 248 Methanol/water 58 60.92 60.91 3.79 3.80 13.75 13.77 
4c -CH3 -Cl C31H22Cl2N6OS2 629.58 244 Ethanol/water 62 59.14 59.16 3.52 3.55 13.35 13.37 
4d -CH3 -OCH3 C32H25ClN6O2S2 625.16 252 Methanol 66 61.48 61.52 4.03 4.02 13.44 13.48 
4e -C2H5 -Cl C32H24Cl2N6OS2 643.60 258 Pet. ether 61 59.72 59.75 3.76 3.78 13.06 13.10 
4f -C2H5 -OCH3 C33H27ClN6O2S2 639.18 262 Acetone 52 62.01 62.04 4.26 4.25 13.15 13.17 
4g -C6H5 -Cl C36H24Cl2N6OS2 691.65 266 n-Hexane 56 62.51 62.55 3.50 3.55 12.15 12.18 
4h -C6H5 -OCH3 C37H27ClN6O2S2 687.23 268 n-hexane 60 64.66 64.69 3.96 3.99 12.23 12.25 
 




55.9, 53. FAB mass peaks [M
+
] m/e 642.60, 608.15, 
532.05, 504.04, 421.51, 396.87, 368.81, 329.82, 
313.78, 246.01, 230.24, 203.02, 191.26, 164.24, 





























H NMR (DMSO-d6) δ 
2.36 (s, 3H, ―CH3), 3.39 (s, 3H, ―OCH3), 4.21 (q, 
2H, ―CH2), 4.90 (s, 2H, ―CH of benzothiazole), 
7.65-6.65 (m, 16H, Ar―H), 7.66 (s, H, ―CH of 
oxazole), 8.12 (N=CH―Ar). 
13
C-NMR (75 MHz, 
CDCl3) δ 160.7, 150.6, 142.6, 141.6, 140.0, 138.1, 
132.7, 129.8, 129.2, 128.9, 127.7, 126.1, 126.0, 125.1, 
121.0, 119, 118.5, 117.4, 114.5, 114.3, 113.7, 66.5, 
57.4, 55.9, 34.3. FAB mass peaks [M
+
] m/e 638.18, 
607.15, 603.73, 527.64, 504.04, 392.45, 325.40, 
313.78, 246.01, 230.24, 203.02, 191.02, 164.24, 






























H NMR (DMSO-d6) δ 
4.91 (s, 2H, ―CH of benzothiazole), 7.68 (s, H, 
―CH of oxazole), 8.10-6.75 (m, 21H, Ar―H), 8.14 
(N=CH―Ar). 
13
C-NMR (75 MHz, CDCl3) δ 160.7, 
150.6, 142.6, 141.6, 140.0. 138.1, 132.7, 129.8, 129.2, 
128.9, 127.7, 126.8, 126.1,126.0, 125.4, 125.1, 124.3, 
121.0, 119, 118.5, 117.4, 114.5, 114.3, 113.7,66.5, 
55.9, 54.9, 41.2, 12.3. FAB mass peaks [M
+
] m/e 
690.65, 656.19, 580.10, 566.08, 444.91, 441.54, 
377.87, 368.81, 313.78, 306.35, 246.01, 239.30, 
230.24, 212.29, 203.02, 139.56, 136.18, 123.07, 






























H NMR (DMSO-d6) δ 
3.36 (s, 3H, ―OCH3), 4.92 (s, 2H, ―CH of 
benzothiazole), 7.65-6.65 (m, 21H, Ar―H), 7.69  
(s, H, ―CH of oxazole), 8.12 (N=CH―Ar).  
13
C-NMR (75 MHz, CDCl3) δ 160.7, 150.6, 149.1, 
141.6, 140.0. 138.1, 132.7, 129.9, 129.7, 129.2, 128.9, 
127.7, 127.6, 126.8, 126.1, 126.0, 125.4, 124.3, 121.0, 
119.1, 119.0, 118.5, 118.3, 117.4, 114.3, 113.7, 66.5, 
57.3, 55.9. FAB mass peaks [M
+
] m/e 686.23, 656.19, 
575.68, 552.08, 469.55, 440.11, 373.45, 364.39, 
313.78, 306.35, 246.01, 239.30, 230.24, 212.29, 





Synthesis of (compound 2’): A solution of 2-
chloro-1-(2-(4-chlorophenyl) benzo[d]thiazol-3(2H)-
yl)ethanone (compound 1) (0.01 mol) in ethanol  
(10 mL) in absolute ethanol (22 mL) was added to 
thiourea (0.01 mol). The reaction mixture was taken 
in an Erlenmeyer type flask and assisted by ultrasonic 
irradiation for 06 min. The progress of the reaction 
was monitored by TLC. After completion of the 
reaction product was cooled and poured into ice cold 
water. The resulting precipitate was filtered off, 
washed with ethanol and recrystallised from 
ethanol/water. The CHN and physical characterization 





 (C―Cl), 762 cm
–1
 (C―C), 1241 
cm
–1
 (C―N), 1544 cm
–1
 (C=C for aromatic 
compound), 681 cm
–1
 (C―S―C), 3040 cm
–1
 (C―H 
for aromatic compound), 1579 cm
–1





H NMR (DMSO-d6) δ 4.94 (s, IH, CH of 
benzothiazole), 6.12 (s, 2H, ―NH2), 7.50 (s, H, ―CH 
of thiazole), 7.65-6.85 (m, 8H, Ar―H). 
13
C-NMR (75 
MHz, CDCl3) δ 169.0, 141.6, 140.0, 139.0, 132.7, 
129.9, 128.9, 127.6, 126.4, 124.3, 113.7, 108, 66.4, 
40.0. FAB mass peaks [M
+
] m/e 344.86, 310.42, 
296.40, 246.74, 234.32, 219.31, 212.29, 136.20, 





Synthesis of compound (3a’-3d’): A solution of 4-
(2-(4-chlorophenyl)benzo[d] thiazol-3(2H)-yl)thiazol-
2-amine (compound 2’) (0.01 mol) in ethanol (75 mL) 
was added 3-substituted-2-hydrobenzo[d]thiazole-2-




carbaldehyde (0.01 mol) in ethanol (15 mL) in the 
presence of 2-3 drop of glacial acetic acid. The 
reaction mixture was taken in an Erlenmeyer type 
flask and assisted by ultrasonic irradiation for 10 min. 
The progress of the reaction was monitored by TLC. 
The solvents were recovered under reduce pressure, 
then the product was cooled and poured in to ice cold 
water, The resulting precipitate was filtered off, 
washed with ethanol and recrystallised from 
ethanol/water. The CHN and physical characterization 














 (C―N), 1545 cm
–1
 (C=C for 
aromatic compound), 685 cm
–1
 (C―S―C), 3044 cm
–1
 
(C―H for aromatic compound), 1575 cm
–1





H NMR (DMSO-d6) δ 4.90 (s, 2H, ―CH 
of benzothiazole), 7.50 (s, H, ―CH of thiazole), 7.65-
6.85 (m, 12H, Ar―H), 8.12 (N=CH―Ar), 9.30 (s, 1H, 
―NH of benzothiazole exchangeable with D2O). 
13
C-
NMR (75 MHz, CDCl3) δ 171.1, 163.7, 146.6, 141.6, 
140.0, 132.7, 129.2, 128.9, 127.6, 126.0, 124.3, 119.4, 
117.4, 113.7, 66.5, 57.5, 40.0. FAB mass peaks [M
+
] 
m/e 492.06, 382.52, 356.88, 344.86, 310.42, 296.40, 
246.74, 234.32, 219.31, 212.29, 163.04, 136.20, 136.20, 




methylene) thiazol-2-amine (3b’) 











 (C=C for 
aromatic compound), 685 cm
–1
 (C―S―C), 3044 cm
–
1




H NMR (DMSO-d6) δ 2.34 (s, 3H, CH3), 4.90 (s, 2H, 
CH of benzothiazole), 7.48 (s, H, ―CH of thiazole), 
7.65-6.85 (m, 12H, Ar―H), 8.12 (N=CH―Ar).  
13
C-NMR (75 MHz, CDCl3) δ 171.1, 163.7, 146.6, 
141.6, 140.0, 132.7, 129.2, 128.9, 127.6, 126.1, 125.1, 
124.3, 119.4, 118.5, 114.5, 66.5, 61.9, 40.0, 34.3. 
FAB mass peaks [M
+
] m/e 506.04, 492.06, 396.55, 
382.52, 260.03, 356.88, 344.86, 310.42, 296.40, 
246.74, 234.32, 219.31, 212.29, 177.25, 163.04, 




methylene) thiazol-2-amine (3c’) 









 (C―N), 1545 cm
–1
 (C=C for 
aromatic compound), 685 cm
–1
 (C―S―C), 3044 cm
–1
 





NMR (DMSO-d6) δ 2.35 (t, 3H, CH3), 4.22 (q, 2H, 
CH2), 4.90 (s, 2H, CH of benzothiazole), 7.46 (s, H, 
―CH of thiazole), 7.75-6.75 (m, 12H, Ar―H), 8.11 
(N=CH―Ar). 
13
C-NMR (75 MHz, CDCl3) δ 171.1, 
163.7, 146.6, 142.6, 141.6, 140.0, 132.7, 129.2, 128.9, 
127.6, 126.1, 125.1, 124.3, 119.4, 118.5, 114.5, 66.5, 
59.4, 41.2, 12.3. FAB mass peaks [M
+
] m/e 520.11, 
492.06, 485.66, 409.06, 382.52, 274.39, 356.88, 
344.86, 310.42, 296.40, 246.74, 234.32, 219.31, 
212.29, 191.28, 163.04, 136.20, 150.22, 111.55, 




methylene) thiazol-2-amine (3d’) 









 (C―N), 1545 cm
–1
 (C=C for 
aromatic compound), 685 cm
–1
 (C―S―C), 3044 cm
–
1




H NMR (DMSO-d6) δ 4.90 (s, 2H, CH of 
benzothiazole), 7.45 (s, H, ―CH of thiazol), 7.85-
6.85 (m, 17H, Ar―H), 8.11 (N=CH―Ar). 
13
C-NMR 
(75 MHz, CDCl3) δ 171.1, 163.7, 149.1, 141.3, 140.0, 
132.7, 129.9, 129.7, 129.2, 128.9, 127.7, 126.1, 124.3, 
119.3, 118.3, 117.4, 113.7, 66.5, 61.8. FAB mass peaks 
[M
+
] m/e 568.16, 533.71, 522.23, 492.06, 457.62, 
382.52, 356.88, 344.86, 339.32, 322.05, 274.39, , 
Table VI — Physical characterization and elemental analysis of 4-(2-(4-chlorophenyl)benzo[d]thiazol-3(2H)-yl)-N-((3-substituted-2,3-
dihydrobenzo [d]thiazol-2-yl)methylene)thiazol-2-amine (3a’-3d’) 




Yeld % Elemental analysis 
C% H% N% 
Calcd Found Calcd Found Calcd Found 
2’  C16H12ClN3S2 345.01 158 Ethanol/water 58 55.56 55.63 3.50 3.52 12.15 12.16 
3a’ -H C24H17ClN4S3 493.06 168 Ethanol 60 58.46 58.51 3.48 3.49 11.36 11.39 
3b’ -CH3 C25H19ClN4S3 507.09 172 Ethanol/water 62 59.21 59.24 3.78 3.79 11.05 11.09 
3c’ -C2H5 C26H21ClN4S3 521.11 177 Methanol 66 59.92 59.88 4.06 4.08 10.75 10.77 
3d’ -C6H5 C30H21ClN4S3 569.16 185 Ethanol/water 61 63.31 63.32 3.72 3.78 9.84 9.87 
 




246.74, 239.32, 219.31, 212.29, 191.28, 163.04, 150.22, 
136.20, 111.55, 99.14, 84.12, 77.11, 28.05. 
 




Synthesis of compound (4a’-4h’): A solution of the 
compound 3a’-3d’ (0.1 mol) in ethanol was added to a 
solution of diazonium salt {(prepared by chloro/ 
methoxy substituted aniline (0.1 mol) in glacial acetic 
(4mL) was added to conc. HCl (2 mL) at 0-4
o
C and 
20% sodium nitrite solution (2 mL)} with constant 
stirring in pyridine (20 mL) below 0
o
C. The reaction 
mixture was taken in an Erlenmeyer type flask and 
assisted by ultrasonication for 05 min. in ice bath. The 
progress of the reaction was monitored by TLC.  
The resulting solids were washed with water, 
recrystallised from suitable solvent and dried under 
vacuum over anhydrous CaCl2. Their CHN and 
physical characterization data of the compounds are 































H NMR (DMSO-d6) δ 4.90 
(s, 2H, ―CH of benzothiazole), 7.65-6.75 (m, 16H, 
Ar―H), 7.54 (s, H, ―CH of thiazole), 8.15 
(N=CH―Ar), 9.30 (s, 1H, ―NH of benzothiazole 
exchangeable with D2O). 
13
C-NMR (75 MHz, CDCl3) δ 
171.7, 146.6, 141.6, 140.0, 134.3, 132.7, 130.2, 129.2, 
128.9, 127.6, 126.0, 124.3, 119.0, 117.4, 113.7, 66.5, 
58.0. FAB mass peaks [M
+
] m/e 630.62, 597.17, 562.73, 
520.08, 495.01, 409.53, 384.89, 329.85, 301.78, 246.74, 
234.32, 219.31, 212.29, 191.24, 163.04, 136.20, 136.20, 
























 (C―H for aromatic 
compound), 1565 cm
–1





NMR (DMSO-d6) δ 3.39 (s, 3H, ―OCH3), 4.90  
(s, 2H, ―CH of benzothiazole), 7.52 (s, H, ―CH  
of thiazole), 7.65-6.75 (m, 16H, Ar―H), 8.11 
(N=CH―Ar), 9.30 (s, 1H, ―NH of benzothiazole 
exchangeable with D2O). 
13
C-NMR (75 MHz, CDCl3) 
δ 171.7, 142.6, 141.6, 140.0. 134.3, 132.7, 130.2, 
129.2, 128.9, 127.7, 126.1, 125.1, 119, 118.5, 117.4, 
114.5, 113.7,66.5, 57.4, 34.3. FAB mass peaks [M
+
] 
m/e 627.20, 597.17, 562.73, 520.08, 495.01, 409.53, 
384.89, 329.85, 301.78, 246.74, 219.29, 205.25, 





























H NMR (DMSO-d6) δ 
2.35 (s, 3H, ―CH3), 4.90 (s, 2H, ―CH of 
benzothiazole), 7.50 (s, H, ―CH of thiazole), 7.65-
6.75 (m, 16H, Ar―H), 8.13 (N=CH―Ar). 
13
C-NMR 
(75 MHz, CDCl3) δ 171.7, 142.6, 141.6, 140.0. 134.3, 
Table VII — Physical characterization and elemental analysis of (Z)-N'-(4-(2-(4-chlorophenyl)benzo[d]thiazol-3(2H)-yl)thiazol-2-yl)-N-
(4-substituted phenylimino) -3-substituted-2,3-dihydrobenzo[d]thiazole-2-carboxamidine (4a’-4h’) 







C% H% N% 
Calcd Found Calcd Found Calcd Found 
4a’ -H -Cl C30H20Cl2N6S3 631.62 244 Ethanol 55 57.05 57.12 3.19 3.18 13.31 13.17 
4b’ -H -OCH3 C31H23ClN6OS3 627.20 251 Methanol/water 54 59.36 59.32 3.70 3.72 13.40 13.44 
4c’ -CH3 -Cl C31H22Cl2N6S3 645.64 248 Ethanol/water 58 57.69 57.71 3.43 3.48 13.02 13.07 
4d’ -CH3 -OCH3 C32H25ClN6OS3 641.22 258 Methanol 62 59.94 59.98 3.93 3.92 13.11 13.15 
4e’ -C2H5 -Cl C32H24Cl2N6S3 659.67 264 Pet. ether 59 58.26 58.28 3.67 3.68 12.74 12.77 
4f’ -C2H5 -OCH3 C33H27ClN6OS3 655.25 268 Acetone 51 60.49 60.52 4.15 4.18 12.83 12.84 
4g’ -C6H5 -Cl C36H24Cl2N6S3 707.71 264 n-Hexane 50 61.10 61.12 3.42 3.48 11.87 11.90 
4h’ -C6H5 -OCH3 C37H27ClN6OS3 703.29 270 n-hexane 56 63.19 63.22 3.87 3.90 11.95 11.97 
 




132.7, 130.2, 129.2, 128.9, 127.7, 126.8, 126.1,126.0, 
125.1, 119, 18.5, 117.4, 114.5, 113.7,66.5, 54.9, 41.2, 
12.3. FAB mass peaks [M
+
] m/e 644.64, 610.19, 575.74, 
534.09, 506.08, 471.63, 409.53, 397.91, 330.84, 329.85, 
288.36, 246.74, 215.80, 205.25, 150.22, 139.56, 136.20, 






























H NMR (DMSO-d6) δ 2.38 (s, 3H, ―CH3), 
3.39 (s, 3H, ―OCH3), 4.92 (s, 2H, ―CH of 
benzothiazole), 7.50 (s, H, ―CH of thiazol), 7.65-6.75 
(m, 16H, Ar―H), 8.13 (N=CH―Ar). 
13
C-NMR (75 
MHz, CDCl3) δ 171.7, 149.1, 141.6, 140.0. 134.3, 
132.7, 130.2, 129.7, 129.2, 128.9, 127.7, 126.8, 
126.1,126.0, 125.1, 119.1, 119.0, 118.5, 118.3, 117.4, 
114.5, 113.7, 66.5, 57.3. FAB mass peaks [M
+
] m/e 
640.22, 610.19, 605.77, 575.74, 534.04, 506.08, 394.49, 
329.84, 284.35, 260.35, 246.74, 246.31, 219.29, 205.25, 





























H NMR (DMSO-d6) δ 
2.35 (s, 3H, ―CH3), 4.24 (q, 2H, ―CH2), 4.91 (s, 2H, 
―CH of benzothiazole exchangeable), 7.49 (s, H, 
―CH of thiazole), 7.75-6.75 (m, 16H, Ar―H), 8.12 
(N=CH―Ar). 
13
C-NMR (75 MHz, CDCl3) δ 171.7, 
160.7, 146.6, 141.6, 140.0, 134.3, 132.7, 130.2, 129.8, 
129.2, 128.9, 127.6, 126.0, 124.3, 121.0, 119.0, 117.4, 
114.3, 113.7, 66.5, 58.0, 55.9, 53.0. FAB mass peaks 
[M
+
] m/e 658.67, 624.22, 589.76, 561.70, 519.05, 
409.53, 384.87, 329.00, 274.37, 246.02, 219.01, 
212.06, 191.07, 205.25, 191.26, 164.06, 162.03, 





























H NMR (DMSO-d6) δ 2.36 (s, 3H, 
―CH3), 3.39 (s, 3H, ―OCH3), 4.21 (q, 2H, ―CH2), 
4.90 (s, 2H, ―CH of benzothiazole), 7.48 (s, H, ―CH 
of thiazole), 7.65-6.65 (m, 16H, Ar―H), 8.16 
(N=CH―Ar). 
13
C-NMR (75 MHz, CDCl3) δ 171.7, 
160.7, 142.6, 141.6, 140.0, 132.7, 129.8, 129.2, 128.9, 
127.7, 126.1, 126.0, 125.1, 121.0, 119, 118.5, 117.4, 
114.5, 114.3, 113.7,66.5, 57.4, 55.9, 34.3. FAB mass 
peaks [M
+
] m/e 654.25, 619.80, 589.76, 561.70, 519.05, 
408.51, 380.45, 329.00, 325.40, 274.32, 246.31, 219.01, 
212.05, 191.07, 164.06, 162.02, 135.06, 136.02, 111.55, 
107.05, 83.99, 56.05, 29.11. The pathway fragmentation 
pattern of the mass spectrum of the compound 4f’ is 






























H NMR (DMSO-d6) δ 4.91 (s, 2H, ―CH of 
benzothiazole), 7.46 (s, H, ―CH of thiazole), 8.10-6.75 
(m, 21H, Ar―H), 8.17 (N=CH―Ar). 
13
C-NMR (75 
MHz, CDCl3) δ 171.7, 160.7, 142.6, 141.6, 140.0. 
132.7, 129.8, 129.2, 128.9, 127.6, 126.8, 126.1,126.0, 
125.1, 124.3, 121.0, 119, 118.5, 117.4, 114.5, 114.3, 
113.7,66.5, 55.9, 54.9, 41.2, 12.3. FAB mass peaks [M
+
] 
m/e 706.71, 672.26, 637.81, 630.61, 596.16, 520.11, 
460.98, 384.87, 377.87, 329.84, 301.76, 267.31, 246.74, 
239.30, 219.29, 212.05, 166.67, 164.20, 135.18, 111.55, 






























H NMR (DMSO-d6)  
δ 3.36 (s, 3H, ―OCH3), 4.92 (s, 2H, ―CH of 
benzothiazole), 7.65-6.65 (m, 21H, Ar―H), 7.45 (s, H, 
―CH of thiazole), 8.17 (N=CH―Ar). 
13
C-NMR  
(75 MHz, CDCl3) δ 171.7, 160.7, 149.1, 141.6, 141.3, 
140.0. 132.7, 129.9, 129.2, 128.9, 127.7, 127.6, 126.8, 




126.1, 126.0, 124.3, 121.0, 119.1, 119.0, 118.5, 118.3, 
117.4, 114.3, 113.7, 66.5, 57.3, 55.9. FAB mass peaks 
[M
+
] m/e 702.29, 667.84, 637.81, 591.74, 568.15, 
520.06, 492.05, 456.56, 425.52, 373.45, 350.43, 
329.84, 274.32, 267.32, 246.74, 219.29, 191.21, 





Antimicrobial screening of the newly synthesized 
compound were evaluated using agar well diffusion 
method
28
. The biological activity of the compounds 
and standard drug (antibacterial lmipenem and 
antifungal miconazol) were studied against the 
Staphylococcus aureus, Bacillus subtilis (as gram 
positive bacteria) and Pseudomonas aeruginosa, 
Escherichia coli, Salmonella typhi (as gram negative 
bacteria) and fungi Rizoctonia sp., Aspergillus sp., 
Penicillium sp. All strains were obtained from 
Microbial Type Collection and Gene Bank, Institute 
of Microbial Technology (IMTECH) Chandigarh, 
India. The solution of different concentration 1, 1.5 
and 2 mg/mL of each compound including standard 
drug lmipenem and miconazol in DMSO was 
prepared for testing against spore germination of 
fungi and bacteria. Centrifuged pellets of 
microorganism from a 24 h old culture containing 
approximately 10
4
 CFU (colony forming unit) per mL 
were spread on the surface of Muller Hinton Agar 
media plates. Wells with 6 mm diameter made, and 
 
 
Figure 1 — The pathway fragmentation pattern of the mass spectrum of compound (4f’) 
 




then solution of test compound was filled to the wells. 
The plates were incubated at 30
o
C for 24h. The 
activity of the compounds was determined by 
measuring diameter of the inhibition zone (in mm) 





One way ANOVA analysis is done with a suitable 
transformation to know the significance difference in 
the mean biological action. The interaction between 
the three factors temperature, concentration and zone 
of inhibition, in which temperature was fixed and two 
factors concentration and zone of inhibition were 
variable, in Table VIII the investigation was response 
in term of zone of inhibition (mm) at different 
experimental condition. The mode F-value 14.2 and 
mode P-value <.0001 implied the mode is significant. 
In Table IX, the mode F-value and P-value were 
Table VIII — One way ANOVA analysis is done, the zone of inhibition fungal strain using newly synthesized compounds and standard 
drug Miconazole Results were obtained using the link, http://vassarstats.net/anova1u.html 
ANOVA Summary Correlated Samples k=4 
Source SS df MS F P 
Treatment 
[between groups] 
2838.7969 3 946.2656 14.2 <.0001 
Error 3998.4375 60 66.6406   
Ss/Bl      
Total 6837.2344 63    
Ss/BI = Subjects or Blocks depending on the design. 
Applicable only to correlate samples ANOVA. 
Tukey HSD Test. 
HSD[.05]=7.65; HSD[.01]=9.4 
M1 vs M2 P<.05 
M1 vs M3 P<.01 
M1 vs M4 nonsignificant 
M2 vs M3 P<.01 
M2 vs M4 nonsignificant 
M3 vs M4 P<.01 
M1 = mean of Sample 1 
M2 = mean of Sample 2 
and so forth. 
HSD = the absolute [unsigned] difference between any two sample 
means required for significance at the designated level. HSD[.05] 
for the .05 level; 
HSD[.01] for the .01 level. 
The interaction between the three factors temperature, concentration and zone of inhibition, in which temperature was fixed and two 
factors concentration and zone of inhibition were variable. 
 
Table IX — One way ANOVA analysis is done, the zone of inhibition of bacterial strain using newly synthesized compounds and 
standard drug Imipenem Results were obtained using the link, http://vassarstats.net/anova1u.html 
ANOVA Summary Correlated Samples k=5 
Source SS df MS F P 
Treatment [between groups] 12980.2 4 3245.05 51.89 <.0001 
Error 4690.1875 75 62.5358   
Ss/Bl      
Total 17670.3875 79    
Ss/BI = Subjects or Blocks depending on the design. 
Applicable only to correlate samples ANOVA. 
Tukey HSD Test. 
HSD[.05]=7.83; HSD[.01]=9.45 
M1 vs M2 nonsignificant 
M1 vs M3 P<.01 
M1 vs M4 P<.01 
M1 vs M5 P<.01 
M2 vs M3 P<.01 
M2 vs M4 P<.01 
M2 vs M5 P<.01 
M3 vs M4 nonsignificant 
M3 vs M5 P<.05 
M4 vs M5 nonsignificant 
M1 = mean of Sample 1 
M2 = mean of Sample 2 
and so forth. 
HSD = the absolute [unsigned] difference between any two sample 
means required for significance at the designated level. HSD[.05] 
for the .05 level; 
HSD[.01] for the .01 level. 
The interaction between the three factors temperature, concentration and zone of inhibition, in which temperature was fixed and two 
factors concentration and zone of inhibition were variable. 
 




significant 51.89 and <.0001, respectively. Results 






The newly synthesized compounds having R  
(–C2H5) substituted group at the third position of 
benzothiazole were shown to be more biologically 
active as compare to other compounds. Compound 
4e’ {N'-(4-(2-(4-chlorophenyl)benzo[d]thiazol-3(2H)-
yl)thiazol-2-yl)-N-(4-chlorophenylimino)-3-ethyl-2,3-
dihydrobenzo[d]thiazole-2-carboxamidine} was the 
most active compound as compare to reference drug.. 
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